Highlights
- 1Nature · 2021
- 2Gastroenterology · 2020
- 3Scientific reports · 2021
Publications
Funding
Active
13 grants- Co-IR01DK148866-01Decoding endothelial metabolic control of liver homeostasis and response to damage.National Institute of Diabetes and Digestive and Kidney Diseases · 2026–2031
- PIR01AI195435-02Spatial omics to understanding HBV control in people with HIV coinfectionNational Institute of Allergy and Infectious Diseases · 2025–2030
- Sub-PIR01DK146438-01Mechanisms regulating competency of hepatocyte plasticityNational Institute of Diabetes and Digestive and Kidney Diseases · 2026–2029 · via Cincinnati Children's Hospital Medical Center
- Sub-PIR01AI187598-02Immune analysis of the HBsAg seroclearance response terminating chronic HBVNational Institute of Allergy and Infectious Diseases · 2024–2029 · via The Regents of the University of California, San Francisco
- Sub-PIR01AI107301-13Genetic Viral and Host Adaptations to Breach Species Barriers of HCVNational Institute of Allergy and Infectious Diseases · 2018–2028 · via Princeton University· 2 renewals
- KPF31DK148095-01A1Elucidating the mechanistic relationship between a genetic variant of interest and increased MASLD predisposition in humansNational Institute of Diabetes and Digestive and Kidney Diseases · 2026–2028Fellowship
- KPR01AI173504-04Impact of SARS-CoV-2 infection on respiratory viral immune responses in children with and without asthmaNational Institute of Allergy and Infectious Diseases · 2023–2028
- PIR01DK138677-03Mechanisms of epithelial-mesenchymal crosstalk in intrahepatic biliary formationNational Institute of Diabetes and Digestive and Kidney Diseases · 2024–2028
- MPIR01DK132879-01A1Assessing the Impact of SARS-CoV-2 on Adipose Tissue Function and Glucose HomeostasisNational Institute of Diabetes and Digestive and Kidney Diseases · 2023–2028
- Co-I80NSSC24K1052Spaceflight and Regolith Induced Mitochondrial Stress Mitigated by miRNA-based CountermeasuresNational Aeronautics and Space Administration · 2024–2026
- Sub-PIBIDMC 223051-03Role of SARS-CoV-2 ion channel ORF3a in COVID-19-associated thrombosisAmerican Heart Association · 2022–2026 · via Beth Israel Deaconess Medical Center, Inc.No publications yet
- PIR01DK121072-05Optimization of the engineered 3D hepatic microenvironment enhances pluripotent stem cell derived hepatocyteNational Institute of Diabetes and Digestive and Kidney Diseases · 2020–2026· 2 renewals
- Sub-PIUWSC13448Mid-terminal human synthetic liver organogenesisPaul G. Allen Family Foundation · 2021–2025 · via University of Washington, The
Completed grants (16)
- PIR01CA234614-05Modeling Hepatoblastoma using pluripotent stem cell derived hepatocyte-like cellsNational Cancer Institute · 2019–2025
- Co-IGIRF 227268-01Colorectal Cancer (CRC) Cellular Heterogeneity, Metastasis, and a Spatially-resolved Molecular Atlas for ColonGastro-Intestinal Research Foundation · 2022–2025
- Sub-PIC22483443Value Proposition & Market" and "Applicability to Future Infectious Disease ThreatsNew York State Empire State Development Fund · 2023–2025 · via Memorial Sloan Kettering Cancer Center
- PIW81XWH-21-1-0978Delineating the role of genetic mutations in Hepatoblastoma development and phenotypesU.S. Department of Defense · 2021–2024
- MPIR01DK130454-03Decode the Impact of SARS-CoV-2 on Human PancreasNational Institute of Diabetes and Digestive and Kidney Diseases · 2021–2024
- MPIUL1TR002384-01Clinical and Translational Science Center - UL1National Center for Advancing Translational Sciences · 2017–2022
- Co-IR01DK119667-02S1Metallothionein 1E as a Central Regulator of Human Pancreatic Beta Cell Function and SurvivalNational Institute of Diabetes and Digestive and Kidney Diseases · 2020–2022
- Sub-PIMSKCC 184475-01Thompson Family Foundation Grant for Pancreatic CancerThe Thompson Family Foundation, Inc. · 2018–2022 · via Sloan-Kettering Institute for Cancer ResearchNo publications yet
- Co-IPSF 210730-01Targeting Cellular Protein Kinases As Treatment For COVID-19Pershing Square Foundation · 2020–2021
- Co-IBMGF INV-018723COVID-19 CTA: Compound screening using organoid modelBill & Melinda Gates Foundation · 2020–2021
- Co-IADA 204683-01Determine the Impact of SARS-CoV-2 infection on Human Pancreatic Endocrine CellsAmerican Diabetes Association · 2020–2021
- Sub-PIW81XWH1810237Modeling Human Hepatocellular Carcinoma in Humanized MiceU.S. Department of Defense · 2018–2020 · via Princeton UniversityNo publications yet
- PIR03DK117252-02Identification of Hepatitis B Virus Permissiveness FactorsNational Institute of Diabetes and Digestive and Kidney Diseases · 2018–2020
- Co-IDFI 180508-01Evaluation of Anti-ZIKV Drug CandidatesDaedalus Fund for Innovation (Weill Cornell) · 2017–2019
- PIK08DK101754-05New Hepatocyte Model Systems to Study Hepatitis B Virus InfectionNational Institute of Diabetes and Digestive and Kidney Diseases · 2014–2019· 2 renewals
- Sub-PIR21AI117213-02Impact of Species-Specific Host Responses on Restriction of Hepatotropic VirusesNational Institute of Allergy and Infectious Diseases · 2015–2017 · via Princeton University
Honors & distinctions
- Member · American Society for Clinical Investigation · 2022
Clinical research
Active
2 studies- PIThe Placenta as a Potential Site of SARS-COV-2 Infection and TransmissionWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2020)
- PIImmune and Inflammatory response in the serum and placenta to COVID-19 infection.Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2020)
Completed & closed trials (2)
- PINCT06903338A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart + Elebsiran Combination Therapy in Participants With Chronic HDV Infection (ECLIPSE 1)PHASE3 · Vir Biotechnology · CLOSED TO ACCRUAL (as of 2025)Viral Hepatitis
- PINCT03852719A Multicenter, Open-label, Randomized Phase 3 Clinical Study to Assess Efficacy and Safety of Bulevirtide in Patients With Chronic Hepatitis DeltaPHASE3 · MYR GmbH Pharmaceuticals · IRB STUDY CLOSURE (as of 2020)Chronic Hepatitis Delta
Available technologies
News mentions
- Study Details Surprising Biological Mechanisms Underlying Severe COVID-19December 2, 2024
Severe COVID-19 arises in part from the SARS-CoV-2 virus’s impact on mitochondria, tiny oxygen-burning power plants in cells, which can help trigger a cascade of organ- and immune system-damaging events, suggests a study by investigators at Weill Cornell Medicine, Johns Hopkins Medicine, Children’s Hospital of Philadelphia, and the University of Pittsburgh School of Medicine, along with other members of the COVID-19 International Research Team.
- New Predictors of Metastasis in Patients with Early-Stage Pancreatic CancerJune 28, 2024
Researchers at Weill Cornell Medicine with an international team have used liver biopsies to identify cellular and molecular markers that can potentially be used to predict whether and when pancreatic cancer will spread to an individual’s liver or to another organ.
- SARS-CoV-2 Can Infect Dopamine Neurons Causing SenescenceJanuary 17, 2024
A new study reported that SARS-CoV-2, the virus that causes COVID, can infect dopamine neurons in the brain and trigger senescence—when a cell loses the ability to grow and divide.
- Two Weill Cornell Medicine Faculty Members Inducted into ASCIFebruary 18, 2022
Two Weill Cornell Medicine physician-scientists, Dr. Randy Longman and Dr. Robert Schwartz, have been elected as members of the American Society for Clinical Investigation.
- Old Drug May Have New Trick: Protecting Against COVID-19 Lung InjuryFebruary 8, 2022
An FDA-approved drug that has been in clinical use for more than 70 years may protect against lung injury and the risk of blood clots in severe COVID-19 and other disorders that cause immune-mediated damage to the lungs.
Show 5 more mentions
- Study Reveals a Cause of Heart Damage in COVID-19 and Potential TreatmentsApril 23, 2021
The heart damage seen in many severely ill COVID-19 patients results in part from infection-activated immune cells called macrophages, which infiltrate the heart and secrete cell-damaging chemicals, according to a study co-led by researchers at Weill Cornell Medicine, NewYork-Presbyterian, Icahn School of Medicine at Mount Sinai and Columbia University Irving Medical Center.
- Researchers Create Rapid Diagnostic Tests and Multi-Omics Analytics Platforms for SARS-CoV-2 InfectionMarch 30, 2021
Two distinct diagnostic tests, a host/pathogen RNA sequencing platform, and spatially-resolved tissue mapping tools were created by a multidisciplinary team of Weill Cornell Medicine and NewYork-Presbyterian Hospital-led researchers and used to map SARS-CoV-2 infections at the height of the initial COVID-19 outbreak in New York City.
- New Technique Provides Detailed Map of Lung Pathology in COVID-19March 29, 2021
A team led by investigators at Weill Cornell Medicine and NewYork-Presbyterian has used advanced technology and analytics to map, at single-cell resolution, the cellular landscape of diseased lung tissue in severe COVID-19 and other infectious lung diseases.
- COVID-19 Research Grants Support Weill Cornell Medicine InvestigatorsSeptember 11, 2020
Weill Cornell Medicine has awarded eight grants of $100,000 each to faculty for a variety of research projects on COVID-19, funded by the institution’s Board of Overseers and additional donors. The grants will support studies aimed at understanding fundamental aspects of the disease, the body’s immune response and social determinants of health that affect COVID-19 outcomes.
- Pluripotent Stem Cells Shed Light on How COVID-19 Infects the Pancreas and Liver and Its Relationship with DiabetesJuly 23, 2020
The study of human pluripotent stem cells, which can develop into any cell type in the body, is providing Weill Cornell Medicine and NewYork-Presbyterian investigators with new insights into the virus that causes COVID-19 and how it may infect organs such as the pancreas and liver.
Mentoring
- CRChanel RichardsonPharmacology (PhD) · Class of 2021
- APAnna PeczakPhysiology, Biophysics & Systems Biology (PhD)
External relationships
Advisory/Scientific Board Member
iOrganBio INC · Lime Therapeutics, Inc. · Miromatrix Medical Inc.
Other
Alnylam Pharmaceuticals, Inc. · Novo Nordisk Pharmaceuticals, Inc.